THE FUTURE OF HEPATITIS B TREATMENT...THE FUTURE OF HEPATITIS B TREATMENT Scan the QR code to access...
1
Durable loss of HBsAg with finite therapy ≥30% of individuals HBsAg HBV DNA Anti-HBs Integrated HBV DNA Integrated HBV DNA Integrated HBV DNA cccDNA LIVER SERUM NAs Sterilising cure Complete cure Functional cure Broaden the population of patients eligible for treatment Combination therapy is likely to be required - antiviral + immune modulator Immune modulation 3 CD8+ T cells B cells Disrupting the viral replication cycle 3 Mature nucleocapsid Immature nucleocapsid Subgenomic RNAs cccDNA Integrated HBV DNA Entry inhibitor Target cccDNA Block nucleocapsid assembly Inhibit HBsAg release RNA interference Current guidelines recommend treatment with NAs for patients with HBeAg-positive chronic hepatitis or HBeAg-negative chronic hepatitis¹ The main goal of therapy is to improve survival and quality of life by preventing disease progression and HCC development¹ Viral suppression can be achieved with life-long therapy 1 THE FUTURE OF HEPATITIS B TREATMENT Scan the QR code to access the Hepatic Health website and learn more from Dr Kosh Agarwal on the latest advances towards HBV cure How can we achieve HBV cure? Immune modulation to target HBV • Boost • Reset • Reconfigure • Cure is defined as achievement of functional cure References: 1. EASL Clinical Practice Guidelines. J Hepatol 2017;67:370–98; 2. Lok AS, et al. Hepatology 2017;66:1296–313; 3. Revill PA, et al. Lancet Gastroenterol Hepatol. 2019;4:545–58; 4 :545–58; 4. Coornberg M, et al. Hepatology 2019;doi:10.1016/j.jhep.2019.11.003; 5. Zoulim F. Hepatitis B cure: from discovery to regulatory endpoints in HBV clinical research. 2017. Available at: http://regist2.virology-education.com/2017/4HBV/02_Zoulim.pdf (accessed February 2020);" 6. Testoni B, et al. Semin Liver Dis 2017;37:231–42 cccDNA: covalently closed circular DNA; eGFR: estimated glomerular filtration rate; ETV: entecavir; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HCC: hepatocellular carcinoma; NA: nucleos(t)ide analogue; RIG-I: retinoic acid-inducible gene I; TAF: tenofovir alafenamide; TLR8: toll-like receptor 8 © 2020 Gilead Sciences Europe Ltd. January 2020 IHQ-HBV-2020-01-0033 3. GOALS OF FUTURE HBV THERAPY 4-6 1. THE CONTRIBUTION OF CURRENT CHB TREATMENT OPTIONS 2. STRIVING FOR CURE OF HBV
Transcript of THE FUTURE OF HEPATITIS B TREATMENT...THE FUTURE OF HEPATITIS B TREATMENT Scan the QR code to access...
Durable loss of HBsAg with finite therapy
≥30% of individuals
HBsAg
HBV DNA
Anti-HBs
Integrated HBV DNA
Integrated HBV DNA
Integrated HBV DNA
cccDNALIVER
SERUM
NAs Sterilisingcure
Completecure
Functionalcure
Broaden the population of patients eligible for treatment
Combination therapy is likely to be required - antiviral + immune modulator
Immune modulation3
CD8+ T cellsB cells
Disrupting the viral replication cycle3
Maturenucleocapsid
Immaturenucleocapsid
SubgenomicRNAs
cccDNA
IntegratedHBV DNA
Entry inhibitor
Target cccDNA
Block nucleocapsidassemblyInhibit HBsAg
release
RNAinterference
Current guidelines recommend treatment with NAs for patients with HBeAg-positive chronic hepatitis or HBeAg-negative chronic hepatitis¹
The main goal of therapy is to improve survival and quality of life by preventing disease progression and HCC development¹
Viral suppression can be achieved with life-long therapy1
THE FUTURE OF HEPATITIS B TREATMENT Scan the QR code to access the Hepatic Health website and learn more from Dr Kosh Agarwal on the latest advances towards HBV cure
How can we achieve HBV cure?
Immune modulation to target HBV• Boost• Reset• Reconfigure
• Cure is defined as achievement of functional cure
References: 1. EASL Clinical Practice Guidelines. J Hepatol 2017;67:370–98; 2. Lok AS, et al. Hepatology 2017;66:1296–313; 3. Revill PA, et al. Lancet Gastroenterol Hepatol. 2019;4:545–58; 4 :545–58; 4. Coornberg M, et al. Hepatology 2019;doi:10.1016/j.jhep.2019.11.003;5. Zoulim F. Hepatitis B cure: from discovery to regulatory endpoints in HBV clinical research. 2017. Available at: http://regist2.virology-education.com/2017/4HBV/02_Zoulim.pdf (accessed February 2020);" 6. Testoni B, et al. Semin Liver Dis 2017;37:231–42
cccDNA: covalently closed circular DNA; eGFR: estimated glomerular filtration rate; ETV: entecavir; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HCC: hepatocellular carcinoma; NA: nucleos(t)ide analogue; RIG-I: retinoic acid-inducible gene I; TAF: tenofovir alafenamide; TLR8: toll-like receptor 8
© 2020 Gilead Sciences Europe Ltd.January 2020 IHQ-HBV-2020-01-0033
3. GOALS OF FUTURE HBV THERAPY4-61. THE CONTRIBUTION OF CURRENT CHB TREATMENT OPTIONS
2. STRIVING FOR CURE OF HBV
